US Patent

US11795176 — Solid forms of Alpha-1062 gluconate

Method of Use · Assigned to Alpha Cognition Inc · Expires 2042-01-13 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects crystalline forms of Alpha-1062 gluconate, specifically a solid form known as Form A, characterized by certain X-ray diffraction peaks.

USPTO Abstract

The invention relates to crystalline forms of Alpha-1062 gluconate. In one aspect, the invention relates to a crystalline solid form of Alpha-1062 gluconate (Form A), wherein said crystalline form has prominent peaks at 3.61, 10.98, 14.41 and 18.44 degrees 2-theta (±0.2) in a powder X-ray diffraction pattern. The invention further relates to methods for manufacturing crystalline forms and compositions comprising said crystalline forms.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-713 — benzgalantamine-gluconate
U-713 — benzgalantamine-gluconate
U-713 — benzgalantamine-gluconate

Patent Metadata

Patent number
US11795176
Jurisdiction
US
Classification
Method of Use
Expires
2042-01-13
Drug substance claim
Yes
Drug product claim
No
Assignee
Alpha Cognition Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.